We reasoned that a PRL-humanized PDX host strain should support engraftment and metastasis of luminal ER+ breast cancer while maintaining high engraftment rates of ER-negative breast cancer subtypes that may be less dependent on PRL. The gene discussed is PRL; the disease is breast cancer.